Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Gilotrif

- PMLiVE

Roche’s Evrysdi shows continued improvement in children with spinal muscular atrophy

The progressive neuromuscular disease affects approximately one in every 10,000 babies

- PMLiVE

AstraZeneca’s phase 3 liver cancer study shows continued survival benefit

Hepatocellular carcinoma accounts for about 75% of all primary liver cancers in adults

Katherine Tupper and Holly Joscelyne's top takeaways from the Patients as Partners conference 2023

Patients as Partners – putting people first in clinical trials

Cuttsy+Cuttsy's key takeaways from the Patients as Partners conference 2023

Cuttsy + Cuttsy

Pride Month 2023 – Innovative Trials

Innnovative Trials' Equality & Diversity committee celebrates Pride Month

Innovative Trials

- PMLiVE

Amgen’s supplemental Biologics License Application for Blincyto approved by FDA

The approval for the leukaemia drug was supported by additional data from two phase 3 studies

[Free Whitepaper] 5 Principles for Greater Diversity in Patient Recruitment

Discover how community engagement could enhance diversity in clinical trials patient recruitment

Innovative Trials

- PMLiVE

Innovative Trials attended the Inspire Hertfordshire Award gala dinner

Innovative Trials, a global clinical trial patient recruitment and retention company based in Hertfordshire, has been recognised for its contribution to the county’s economy and business reputation.

Innovative Trials

- PMLiVE

Pfizer’s Talzenna combination receives FDA approval for metastatic prostate cancer

Up to 20% of patients develop metastatic prostate cancer within five to seven years of diagnosis

- PMLiVE

Merck reports positive phase 3 results for Keytruda combination in gastric cancer

Over one million new cases of gastric cancer were diagnosed globally in 2020

- PMLiVE

Roche’s fixed-duration lymphoma treatment granted FDA accelerated approval

Globally around 160,000 people are diagnosed with non-Hodgkin's lymphoma each year

- PMLiVE

Astellas and Cullgen announce protein degrader partnership worth up to $1.9bn

The companies will use Cullgen’s protein degradation platform to discover multiple candidates

- PMLiVE

Medscape Oncology and American Society of Clinical Oncology Collaborate to Offer Cancer-Specific Training to Multidisciplinary Members of the Oncology Care Team

This week Medscape Oncology announced an exciting collaboration with  ASCO® which you read on the Cision PR news wire here or below:The American Society of Clinical Oncology (ASCO®), a leader at...

Medscape Education Global

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links